. 2016 Nov 22;6:37502. doi: 10.1038/srep37502

Table 4. The fold change in the EC₅₀ of parasite growth following drug treatment between 3D7 parasites and those expressing yeast DHODH (yDHODH) in the presence of proguanil (from Table 3), and the fold change in 3D7 parasites treated with each drug in the presence and absence of proguanil.

	Fold Increase with yDHODH		3D7 Fold Decrease with Proguanil
	Control	+1 μM Proguanil
ATV	>50	1.3 (p = 0.3158)	*11 (p =0.0002)*
DSM-1	>44	*19 (p = 0.0001)*	0.7 ( p =0.1105)
MMV020439	*10 (p = 0.0004)*	1.5 (p = 0.1088)	*14 (p =0.0001)*
MMV007571	*96 (p = 0.0054)*	1.5 (p = 0.0709)	*3.5 (p =0.001)*

P-values for fold change (comparing EC₅₀ from 3D7 with corresponding yDHODH and comparing 3D7 with and without proguanil) were calculated using a two-tailed Student’s t-test with Welch’s correction, p-values in bold signify <0.05.

Table 4. The fold change in the EC50 of parasite growth following drug treatment between 3D7 parasites and those expressing yeast DHODH (yDHODH) in the presence of proguanil (from Table 3), and the fold change in 3D7 parasites treated with each drug in the presence and absence of proguanil.

Table 4. The fold change in the EC₅₀ of parasite growth following drug treatment between 3D7 parasites and those expressing yeast DHODH (yDHODH) in the presence of proguanil (from Table 3), and the fold change in 3D7 parasites treated with each drug in the presence and absence of proguanil.